These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 22371632)

  • 1. Role of cytokines and chemokines in non-alcoholic fatty liver disease.
    Braunersreuther V; Viviani GL; Mach F; Montecucco F
    World J Gastroenterol; 2012 Feb; 18(8):727-35. PubMed ID: 22371632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cytokines and chemokines in the development of steatohepatitis.
    Lalor PF; Faint J; Aarbodem Y; Hubscher SG; Adams DH
    Semin Liver Dis; 2007 May; 27(2):173-93. PubMed ID: 17520517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Update on the Chemokine System in the Development of NAFLD.
    Nagata N; Chen G; Xu L; Ando H
    Medicina (Kaunas); 2022 Jun; 58(6):. PubMed ID: 35744024
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Th17 involvement in nonalcoholic fatty liver disease progression to non-alcoholic steatohepatitis.
    Chackelevicius CM; Gambaro SE; Tiribelli C; Rosso N
    World J Gastroenterol; 2016 Nov; 22(41):9096-9103. PubMed ID: 27895397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokines and Chemokine Receptors in the Development of NAFLD.
    Roh YS; Seki E
    Adv Exp Med Biol; 2018; 1061():45-53. PubMed ID: 29956205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory mediators of hepatic steatosis.
    Hijona E; Hijona L; Arenas JI; Bujanda L
    Mediators Inflamm; 2010; 2010():837419. PubMed ID: 20300479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of hepassocin in the development of non-alcoholic fatty liver disease.
    Wu HT; Lu FH; Ou HY; Su YC; Hung HC; Wu JS; Yang YC; Wu CL; Chang CJ
    J Hepatol; 2013 Nov; 59(5):1065-72. PubMed ID: 23792031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis and cytokines in non-alcoholic steatohepatitis.
    Syn WK; Choi SS; Diehl AM
    Clin Liver Dis; 2009 Nov; 13(4):565-80. PubMed ID: 19818305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of inflammation-related genes is altered in gastric tissue of patients with advanced stages of NAFLD.
    Mehta R; Birerdinc A; Neupane A; Shamsaddini A; Afendy A; Elariny H; Chandhoke V; Baranova A; Younossi ZM
    Mediators Inflamm; 2013; 2013():684237. PubMed ID: 23661906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetics in non-alcoholic fatty liver disease.
    Lee J; Kim Y; Friso S; Choi SW
    Mol Aspects Med; 2017 Apr; 54():78-88. PubMed ID: 27889327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.
    Xu B; Jiang M; Chu Y; Wang W; Chen D; Li X; Zhang Z; Zhang D; Fan D; Nie Y; Shao F; Wu K; Liang J
    J Hepatol; 2018 Apr; 68(4):773-782. PubMed ID: 29273476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease.
    Tang Y; Bian Z; Zhao L; Liu Y; Liang S; Wang Q; Han X; Peng Y; Chen X; Shen L; Qiu D; Li Z; Ma X
    Clin Exp Immunol; 2011 Nov; 166(2):281-90. PubMed ID: 21985374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence.
    Mazzolini G; Sowa JP; Atorrasagasti C; Kücükoglu Ö; Syn WK; Canbay A
    Cells; 2020 Nov; 9(11):. PubMed ID: 33187255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
    Wehr A; Baeck C; Ulmer F; Gassler N; Hittatiya K; Luedde T; Neumann UP; Trautwein C; Tacke F
    PLoS One; 2014; 9(11):e112327. PubMed ID: 25372401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions?
    Yilmaz Y
    Aliment Pharmacol Ther; 2012 Nov; 36(9):815-23. PubMed ID: 22966992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microcirculatory disturbances and cellular changes during progression of hepatic steatosis to liver tumors.
    Liebig M; Hassanzada A; Kämmerling M; Genz B; Vollmar B; Abshagen K
    Exp Biol Med (Maywood); 2018 Jan; 243(1):1-12. PubMed ID: 29065724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-C chemokine receptor type 5 deficiency exacerbates alcoholic fatty liver disease through pro-inflammatory cytokines and chemokines-induced hepatic inflammation.
    Park JH; Lee DH; Park MS; Jung YS; Hong JT
    J Gastroenterol Hepatol; 2017 Jun; 32(6):1258-1264. PubMed ID: 27859576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overview of Cellular and Soluble Mediators in Systemic Inflammation Associated with Non-Alcoholic Fatty Liver Disease.
    Marques P; Francisco V; Martínez-Arenas L; Carvalho-Gomes Â; Domingo E; Piqueras L; Berenguer M; Sanz MJ
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of 1-deoxy-sphingolipids with steatosis but not steatohepatitis nor fibrosis in non-alcoholic fatty liver disease.
    Weyler J; Verrijken A; Hornemann T; Vonghia L; Dirinck E; von Eckardstein A; Vanwolleghem T; Michielsen P; Peiffer F; Driessen A; Hubens G; Staels B; Francque S; Van Gaal L
    Acta Diabetol; 2021 Mar; 58(3):319-327. PubMed ID: 33084982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.